IJCRR - Vol 07 Issue 24, December, 2015
VITILIGO ASSOCIATED WITH BREAST CANCER - A REPORT OF TWO CASES
Author: Balasubramanian A., N.S. Kannan
Aim: Aim of this study is to report two cases of generalised vitiligo (GV) who developed cancer (CA) breast.
Case Report: First case is one of CA right breast with history of GV since three years treated with right modified radical mastectomy. Other one is also a case of CA right breast with history of GV since two years treated with neoadjuvant chemotherapy and radiotherapy and followed by right modified radical mastectomy. The second patient developed fresh area of depigmentation at the site of radiotherapy.
Discussion: Even though the association of autoimmune disease (AD) and cancer is well known, there are not much of reports in the literature. The association might be incidental/coincidental or cause and effect relationship. The association might also be cancer (CA) developing in a patient of AD or development of AD in a cancer patient during or after treatment. AD may increase the risk of developing CA or reduce the risk. AD may worsen pre-existing CA or may be a sign of CA regression. Both our cases were known patients of GV who developed CA breast. One of them had developed fresh area of vitiligo after radiotherapy in the post mastectomy site.
Conclusion: Association between AD and CA is well known for a long time. But many aspects of this association with reference to incidence, exact type of association or background of such association whether genetic, environmental or post therapeutic are still not well understood. Our case reports may incite and add up for further studies on these issues..
Keywords: Autoimmune diseases, Generalised vitiligo, Association
Balasubramanian A., N.S. Kannan. VITILIGO ASSOCIATED WITH BREAST CANCER - A REPORT OF TWO CASES International Journal of Current Research and Review. Vol 07 Issue 24, December, 56-58
1. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res. 2012;32(4):1119-36.
2. Alexandrescu DT, Riordan NH, Ichim TE, Kauffman CL, Kabigting F, Dutton CT, et al. On the missing link between inflammation and cancer. Dermatol Online J. 2011;17:10.
3. Sansone P, Bromberg J. Environment, inflammation, and cancer. Curr Opin Genet Dev. 2011;21:80–5.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.
5. Moss SF, Blaser MJ. Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005;2:90–7.
6. Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer. 2009;124:1497–502.
7. Martin DN, Mikhail IS, Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma. 2009;50:541–50.
8. Einefors R, Kogler U, Ellberg C, Olsson H. Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer. SpringerPlus 2013;2:357.
9. Taïeb A, Picardo M. Clinical practice: vitiligo. N Engl J Med 2009;360(2):160–9.
10. Birlea SA, Spritz RA, Norris DA: Vitiligo. In Fitzpatrick’s Dermatology in General Medicine. 8th edition. Edited by Wolff K. New York: McGraw-Hill;
11. Forschner T, Buchholtz S, Stockfleth E. Current state of vitiligo therapy-evidence-based analysis of the literature. J Dtsch Dermatol Ges. 2007;5:467–75.
12. Sehgal VN, Srivastava G. Vitiligo: Compendium of clinicoepidemiological features. Indian J Dermatol Venereol Leprol. 2007;73:149–56.
13. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev 2006;1:CD003263.
14. Tai P, Yu E, Joseph K, Miale T. A review of autoimmune diseases associated with cancer. Front Biosci (Elite Ed). 2010;2:122-6.
15. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol. 2006;18(2):129-34.
16. Wright PD, Venables CW, Dawber RP. Vitiligo and gastric carcinoma. Br Med J. 1970;3:148.
17. Spritz RA. The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med. 2010;2(10):78.
18. Dhawan AK, Verma P, Singal A, Sharma S. Squamous cell carcinoma complicating vitiligo in an Indian man. J Cutan Aesthet Surg. 2012;5(1):36-7.
19. Lassus A, Apajalahti A, Blomqvist K, Mustakallio M, Kiistala U. Vitiligo and neoplasms. Acta Derm Venereol. 1972;52:229–32.
20. Ortonne JP, Pelletier N, Chabanon M, Thivolet J. Vitiligo and cutaneous epitheliomas. Ann Dermatol Venereol. 1978;105:1063– 4.
21. Buckley DA, Rogers S. Multiple keratosis and squamous carcinoma after PUVA treatment of vitiligo. Clin Exp Dermatol. 1996;21:43–5.
22. Attili S, Attili VR. Keratoacanthoma centrifugum marginatum arising in vitiligo: A case report. Dermatol Online J. 2006;28:18.
23. Munshi A, Jain S, Budrukkar A, Jalali R, Sarin R. Radiotherapyinduced depigmentation in a patient with breast cancer. Indian J Cancer 2007;44:157-8.
24. Koo SW, Suh CO, Hann SK. Vitiligo following radiotherapy for carcinoma of the breast. Br J Dermatol 1996;135:852-3.
25. Levine EL, Ribeiro GG. Vitiligo and radiotherapy: The Koebner phenomenon demonstrated in patients with vitiligo undergoing radiotherapy for carcinoma of the breast. Clin Oncol (R Coll Radiol) 1994;6:133-4.
26. Weitzen R, Pfeffer R, Mandel M. Benign lesions in cancer patients: Case 3, Vitiligo after radiotherapy for breast cancer in a woman with depigmentation disorder. J Clin Oncol 2005;23:644.
27. Polat M, Yalηin B, Alli N. Vitiligo at the site of radiotherapy for nasopharyngeal carcinoma. Am J Clin Dermatol 2007;8:247-9.
28. Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol 2002;16:241-8.